Literature DB >> 1281253

Increased expression of preprotachykinin, calcitonin gene-related peptide, but not vasoactive intestinal peptide messenger RNA in dorsal root ganglia during the development of adjuvant monoarthritis in the rat.

L F Donaldson1, A J Harmar, D S McQueen, J R Seckl.   

Abstract

Neuropeptides in dorsal root ganglia (DRG) have been implicated in the pathogenesis of pain and neurogenic inflammation in experimental and clinical arthritis. Recently we demonstrated increased levels of substance P (SP) and calcitonin gene-related peptide (CGRP) confined to innervating DRG in adjuvant-mediated monoarthritis. We have now investigated whether changes in peptide content are reflected in altered neuropeptide gene expression and the time course involved. Using in situ hybridization we found marked increases in expression of beta-preprotachykinin (PPT; 81 +/- 24% rise) and alpha-CGRP (44 +/- 6% rise) mRNAs in innervating (ipsilateral L5) DRG neurones only. These increases occurred at the onset of acute inflammation (8 h) and persisted until chronic arthritis developed after 14 days. There were no changes in the proportion of DRG neurones expressing PPT or CGRP mRNAs. Messenger RNA encoding vasoactive intestinal polypeptide (VIP) was not induced. These data suggest that increased synthesis of PPT and CGRP peptides in DRG may play a role in the pathogenesis both of adjuvant-mediated acute inflammation and chronic arthritis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1281253     DOI: 10.1016/0169-328x(92)90204-o

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  31 in total

1.  Nociception in persistent pancreatitis in rats: effects of morphine and neuropeptide alterations.

Authors:  Louis P Vera-Portocarrero; Ying Lu; Karin N Westlund
Journal:  Anesthesiology       Date:  2003-02       Impact factor: 7.892

2.  Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain.

Authors:  M J Schwei; P Honore; S D Rogers; J L Salak-Johnson; M P Finke; M L Ramnaraine; D R Clohisy; P W Mantyh
Journal:  J Neurosci       Date:  1999-12-15       Impact factor: 6.167

3.  Chapter 9 The dorsal horn and hyperalgesia.

Authors:  Karin N Westlund
Journal:  Handb Clin Neurol       Date:  2006

Review 4.  Innervation of the synovium.

Authors:  P I Mapp
Journal:  Ann Rheum Dis       Date:  1995-05       Impact factor: 19.103

Review 5.  The role of chemosensitive afferent nerves and TRP ion channels in the pathomechanism of headaches.

Authors:  Mária Dux; Péter Sántha; Gábor Jancsó
Journal:  Pflugers Arch       Date:  2012-08-09       Impact factor: 3.657

Review 6.  Pathophysiology of joint pain.

Authors:  B L Kidd; V H Morris; L Urban
Journal:  Ann Rheum Dis       Date:  1996-05       Impact factor: 19.103

7.  Neuropeptide gene expression and capsaicin-sensitive primary afferents: maintenance and spread of adjuvant arthritis in the rat.

Authors:  L F Donaldson; D S McQueen; J R Seckl
Journal:  J Physiol       Date:  1995-07-15       Impact factor: 5.182

8.  Rikkunshito, a traditional Japanese medicine, may relieve abdominal symptoms in rats with experimental esophagitis by improving the barrier function of epithelial cells in esophageal mucosa.

Authors:  Hiroto Miwa; Junichi Koseki; Tadayuki Oshima; Takashi Kondo; Toshihiko Tomita; Jiro Watari; Takayuki Matsumoto; Tomohisa Hattori; Kunitsugu Kubota; Seiichi Iizuka
Journal:  J Gastroenterol       Date:  2009-12-18       Impact factor: 7.527

9.  PACAP-mediated ATP release from rat urothelium and regulation of PACAP/VIP and receptor mRNA in micturition pathways after cyclophosphamide (CYP)-induced cystitis.

Authors:  Beatrice M Girard; Amanda Wolf-Johnston; Karen M Braas; Lori A Birder; Victor May; Margaret A Vizzard
Journal:  J Mol Neurosci       Date:  2008-06-19       Impact factor: 3.444

10.  Autonomic fiber sprouting in the skin in chronic inflammation.

Authors:  Lina Almarestani; Geraldine Longo; Alfredo Ribeiro-da-Silva
Journal:  Mol Pain       Date:  2008-11-14       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.